Pharmacological Management of Pain in Alzheimer's Disease and Related Dementia

阿尔茨海默病和相关痴呆症疼痛的药理学治疗

基本信息

  • 批准号:
    9386225
  • 负责人:
  • 金额:
    $ 12.44万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-08-01 至 2022-05-31
  • 项目状态:
    已结题

项目摘要

Summary: My career goal is to become an independent geriatric pharmacoepidemiologist with expertise in pharmacotherapy quality measurement and outcomes evaluation in the fields of pain and aging. The clinical focus of my research has centered on the management of multi-morbidity in older adults and particularly, the interplay of mental and physical disease and its treatment. One example of combination of health problems is elderly patients who live with Alzheimer's disease and related dementia (ADRD) and also suffer from chronic pain. To date, data on quality of pain medication prescribing and the sequelae of poor pain control in patients with ADRD are scarce. Studies investigating these associations are limited by small sample size, and none has attempted to establish the effect of adequate pain control on preventing mental health (MH) disorders. The goal of my K01 proposed research is to provide preliminary data that improve our understanding of current pain medication prescribing and potential discrepancies between practices and pain guidelines, and to formulate hypotheses for future research regarding the role of pain control in reducing MH problems in ADRD. We propose a longitudinal design using 4 years (2011-2014) of Medicare 5% sample whose billing records are linked to nursing home resident assessment data (Minimum Data Set, MDS, 3.0). Because it is unclear whether MDS 3.0 can accurately detect patients with pain and MH disorders, we first conduct a feasibility study of validating MDS-based pain, depression, and behavioral symptoms against medical records at two nursing homes (Aim 1). With the nationally representative Medicare-MDS data, we explore the quality of pharmacological pain management and its determinants among ADRD and non-ADRD residents with non- cancer pain (Aim 2). The quality will be examined based on five common clinical standards--pain medication selection, pain medication scheduling, pharmacological prevention of drug adverse event, contraindicated medication use, and overall pain control. We then explore the extent to which pain control is associated with a decreased risk for select MH disorders, including depression, behavioral symptoms, anxiety, and sleep disorders in ADRD (Aim 3). This project is well tailored for me to apply the knowledge and skills that will be obtained from training activities with my Primary Mentor, Dr. Almut Winterstein (pharmacoepidemioloy, quality measurement and outcome assessment) and Co-Mentors: Drs. Roger Fillingim (pain), Marco Pahor (aging), Babette Brumback (advanced methods for longitudinal data), and Laurence Solberg (clinical geriatric care and assessment). For further guidance, I enlist the expertise of Dr. Siegfried Schmidt in the field of pain medicine and Dr. Steven DeKosky in ADRD. This K01 award will provide protected time for me to receive training needed to prepare an R01 grant application to examine pain medication practices and their impact on health outcomes in ADRD. The results from this line of research are expected to lead to better pharmacological pain management and improved pain and health outcomes in older adults with cognitive impairments.
摘要:我的职业目标是成为一名独立的老年药物流行病学家, 疼痛和衰老领域的药物治疗质量测量和结果评估。临床 我的研究重点集中在老年人多发病的管理,特别是, 精神和身体疾病相互作用及其治疗。健康问题组合的一个例子是 患有阿尔茨海默病和相关痴呆症(ADRD)并且还患有慢性 痛苦迄今为止,关于止痛药处方质量和患者疼痛控制不良后遗症的数据 与ADRD是稀缺的。调查这些关联的研究受到样本量小的限制, 试图确定适当的疼痛控制对预防心理健康(MH)障碍的影响。的 我提出的K 01研究的目标是提供初步数据,以提高我们对当前 疼痛药物处方和实践与疼痛指南之间的潜在差异,以及 为未来关于疼痛控制在减少ADRD中MH问题中的作用的研究制定假设。 我们提出了一个纵向设计,使用4年(2011-2014)的医疗保险5%的样本,其账单记录是 链接到养老院居民评估数据(最小数据集,MDS,3.0)。因为不清楚 MDS 3.0是否能准确检测出疼痛和MH障碍患者,我们首先进行可行性研究 验证MDS的疼痛,抑郁和行为症状对医疗记录在两个护理 家园(目标1)。通过全国代表性的Medicare-MDS数据,我们探讨了 药物疼痛管理及其在ADRD和非ADRD居民中的决定因素, 癌症疼痛(目标2)。质量将根据五个常见的临床标准进行检查-止痛药 选择,止痛药治疗计划,药物不良事件的药理学预防,禁忌症 药物使用和整体疼痛控制。然后,我们探索疼痛控制与疼痛相关的程度。 降低某些精神分裂症疾病的风险,包括抑郁、行为症状、焦虑和睡眠 ADRD疾病(目标3)。这个项目是为我量身定做的,以应用知识和技能,将 从我的主要导师Almut Winterstein博士的培训活动中获得(药物流行病学、质量 测量和结果评估)和共同导师:Roger Fillingim博士(疼痛),Marco Pahor(衰老), Babette Brumback(纵向数据的先进方法)和Laurence Solberg(临床老年护理和 评估)。为了得到进一步的指导,我请了齐格弗里德施密特医生在疼痛医学领域的专业知识 和ADRD的史蒂文·德科斯基医生这个K 01奖励将为我提供受保护的时间来接受培训 需要准备R 01拨款申请,以检查止痛药的做法及其对健康的影响 ADRD的结果。这项研究的结果有望带来更好的药理学疼痛 管理和改善疼痛和健康结果的老年人认知障碍。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Yu-Jung Wei其他文献

Yu-Jung Wei的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Yu-Jung Wei', 18)}}的其他基金

Pain, Multimorbidity, Opioid-Drug Interactions and Risk for Opioid Use Disorder or Overdose in Older Adults
老年人的疼痛、多重发病、阿片类药物相互作用以及阿片类药物使用障碍或过量的风险
  • 批准号:
    10659436
  • 财政年份:
    2023
  • 资助金额:
    $ 12.44万
  • 项目类别:
Opioid Prescribing Practices and Health Outcomes among Patients with Alzheimer's Disease and Related Dementia
阿尔茨海默病和相关痴呆症患者的阿片类药物处方实践和健康结果
  • 批准号:
    10693853
  • 财政年份:
    2022
  • 资助金额:
    $ 12.44万
  • 项目类别:
Opioid Prescribing Practices and Health Outcomes among Patients with Alzheimer's Disease and Related Dementia
阿尔茨海默病和相关痴呆症患者的阿片类药物处方实践和健康结果
  • 批准号:
    10444395
  • 财政年份:
    2022
  • 资助金额:
    $ 12.44万
  • 项目类别:
Prescription Opioid Use Trajectories and Risk Factors Associated with Opioid-Related Hospitalizations in Older Adults
老年人处方阿片类药物使用轨迹和与阿片类药物相关住院相关的风险因素
  • 批准号:
    10004049
  • 财政年份:
    2019
  • 资助金额:
    $ 12.44万
  • 项目类别:
Pharmacological Management of Pain In Alzheimer's Disease and Related Dementia
阿尔茨海默病和相关痴呆症疼痛的药理学治疗
  • 批准号:
    10161046
  • 财政年份:
    2017
  • 资助金额:
    $ 12.44万
  • 项目类别:
Pharmacological Management of Pain in Alzheimer's Disease and Related Dementia
阿尔茨海默病和相关痴呆症疼痛的药理学治疗
  • 批准号:
    9535032
  • 财政年份:
    2017
  • 资助金额:
    $ 12.44万
  • 项目类别:
Pharmacological Management of Pain in Alzheimer's Disease and Related Dementia
阿尔茨海默病和相关痴呆症疼痛的药理学治疗
  • 批准号:
    10187473
  • 财政年份:
    2017
  • 资助金额:
    $ 12.44万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 12.44万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 12.44万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 12.44万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 12.44万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 12.44万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 12.44万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 12.44万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 12.44万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 12.44万
  • 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
  • 批准号:
    RGPIN-2018-04753
  • 财政年份:
    2022
  • 资助金额:
    $ 12.44万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了